{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:58:53Z","timestamp":1791428333572,"version":"4.3.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Low-density lipoprotein cholesterol (LDL-C) targets remain unmet in many high-risk atherosclerotic cardiovascular disease (ASCVD) patients on statins (\u00b1 ezetimibe). VICTORION-Challenge compared inclisiran with bempedoic acid (BPA) for LDL-C lowering and target attainment in these patients, directly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this Phase 4, open-label study, ASCVD patients with LDL-C \u226570 mg\/dl on statins (\u00b1 ezetimibe) were randomized to inclisiran or BPA. The primary endpoint was a percentage change in LDL-C at Day 150; key secondary endpoints at Day 150 included percentage LDL-C change stratified by ezetimibe use. Secondary endpoints included LDL-C goal attainment and absolute change; treatment-emergent adverse events (TEAEs) were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 402 randomized patients (mean \u00b1 standard deviation age, 63.1 \u00b1 10.7 years; 64.2% men; baseline LDL-C 94.4 \u00b1 28.3 mg\/dl), LDL-C reduction at Day 150 was superior with inclisiran vs BPA [least squares mean \u221256.3% vs \u221215.4%; between-group difference \u221241.0% (95% CI \u221245.7 to \u221236.2); P &amp;lt; .0001]. Inclisiran achieved greater absolute LDL-C reduction at Day 150 (\u221253.4 vs \u221217.5 mg\/dl) regardless of ezetimibe use, with higher LDL-C goal attainment [78.2% vs 20.3%; adjusted odds ratio 16.36 (95% CI 9.72-27.54); descriptive P &amp;lt; .0001]. Inclisiran showed a comparable safety profile vs BPA, with similar rates of TEAEs (63.1% vs 59.8%) and serious TEAEs (8.4% vs 11.6%). The most common TEAEs (inclisiran vs BPA) included nasopharyngitis (10.3% vs 7.5%), hypertension (4.9% vs 4.5%), and myalgia (3.4% vs 5.5%). One non-treatment-related death (inclisiran) was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Inclisiran provided superior LDL-C reduction vs BPA with a consistent safety profile, supporting its use in high-risk patients not achieving guideline-recommended goals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag738","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:16:38Z","timestamp":1788156998000},"source":"Crossref","is-referenced-by-count":1,"title":["Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0024-1643","authenticated-orcid":false,"given":"Ingo","family":"Hilgendorf","sequence":"first","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit\u00e9 , Berlin ,","place":["Germany"]},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) Partner Site Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7542-1956","authenticated-orcid":false,"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Heart Center Freiburg-Bad Krozingen, Faculty of Medicine, University of Freiburg , Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center Bethanien (CCB), Cardioangiologisches Centrum Bethanien , Frankfurt a.M. ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Uebel","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr Gastroenterologie and Fach\u00e4rztliche Innere Medizin, Im Haus der Gesundheit (HdG) Ludwigshafen , Ludwigshafen am Rhein ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"D\u00fcrsch","sequence":"additional","affiliation":[{"name":"ClinPhenomics CVC GmbH , Frankfurt Am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2336-7991","authenticated-orcid":false,"given":"Amir A","family":"Mahabadi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Essen, University of Duisburg-Essen , Essen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8440-975X","authenticated-orcid":false,"given":"Gregor","family":"Nagel","sequence":"additional","affiliation":[{"name":"Hausarztzentrum Butendorf , Gladbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Gerbaulet","sequence":"additional","affiliation":[{"name":"Gemeinschaftspraxis , L\u00f6hne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Hiltl","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Metzner","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Pruckner","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schwaferts","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5459-3954","authenticated-orcid":false,"given":"Jan-Hendrik","family":"Streich","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Thieme","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Gro\u00df-Bsharat","sequence":"additional","affiliation":[{"name":"Winicker Norimed GmbH , Nuremberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-9603","authenticated-orcid":false,"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Technical University of Munich, School of Medicine and Health, German Heart Centre, TUM University Hospital , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0214-3203","authenticated-orcid":false,"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charit\u00e9 , Berlin ,","place":["Germany"]},{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]},{"name":"German Center for Cardiovascular Research (DZHK) Partner Site Berlin , Berlin ,","place":["Germany"]},{"name":"Friede Springer Cardiovascular Prevention Center, Charit\u00e9 - Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026092510311297300_ehag738-B1","author":"World Health Organization"},{"key":"2026092510311297300_ehag738-B2","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/s0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2026092510311297300_ehag738-B3","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/cir.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2026092510311297300_ehag738-B4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2026092510311297300_ehag738-B5","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026092510311297300_ehag738-B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100649","article-title":"The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better","volume":"18","author":"Mhaimeed","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"2026092510311297300_ehag738-B7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092510311297300_ehag738-B8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092510311297300_ehag738-B9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-Sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026092510311297300_ehag738-B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092510311297300_ehag738-B11","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"2026092510311297300_ehag738-B12","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20250640","article-title":"Brazilian guideline on dyslipidemias and prevention of atherosclerosis\u20142025","volume":"122","author":"Rached","year":"2025","journal-title":"Arq Bras Cardiol"},{"key":"2026092510311297300_ehag738-B13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ijcard.2021.12.020","article-title":"Optimal low-density lipoprotein cholesterol target level in Korean acute myocardial infarction patients (&lt;70 mg\/dL vs &lt;55 mg\/dL): based on Korea acute myocardial infarction registry-National Institute of Health","volume":"351","author":"Ahn","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026092510311297300_ehag738-B14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s00392-025-02751-z","article-title":"LipidSnapshot\u2014treatment gaps in hypercholesterolemia in patients with atherosclerotic cardiovascular disease documented by office-based cardiologists and general practitioners in Germany","volume":"115","author":"Weingartner","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"2026092510311297300_ehag738-B15","doi-asserted-by":"publisher","first-page":"685","DOI":"10.18553\/jmcp.2016.22.6.685","article-title":"Patterns of statin use in a real-world population of patients at high cardiovascular risk","volume":"22","author":"Lin","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2026092510311297300_ehag738-B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11883-021-00971-y","article-title":"Oral lipid-lowering treatments beyond statins: too old and outdated or still useful?","volume":"23","author":"Parhofer","year":"2021","journal-title":"Curr Atheroscler Rep"},{"key":"2026092510311297300_ehag738-B17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"2026092510311297300_ehag738-B18","author":"Gemeinsamer Bundesausschuss"},{"key":"2026092510311297300_ehag738-B19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2026092510311297300_ehag738-B20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12872-026-05515-3","article-title":"Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management","volume":"26","author":"Satyam","year":"2026","journal-title":"BMC Cardiovasc Disord"},{"key":"2026092510311297300_ehag738-B21","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092510311297300_ehag738-B22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/biomet\/63.3.655","article-title":"On closed testing procedures with special reference to ordered analysis of variance","volume":"63","author":"Marcus","year":"1976","journal-title":"Biometrika"},{"key":"2026092510311297300_ehag738-B23","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026092510311297300_ehag738-B24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/03007995.2022.2049164","article-title":"Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis","volume":"38","author":"Burnett","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"2026092510311297300_ehag738-B25","doi-asserted-by":"publisher","DOI":"10.31083\/rcm25248","article-title":"Effects of inclisiran, alirocumab, evolocumab, and evinacumab on lipids: a network meta-analysis","volume":"26","author":"Zhang","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"2026092510311297300_ehag738-B26","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2026092510311297300_ehag738-B27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026092510311297300_ehag738-B28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2026092510311297300_ehag738-B29","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"2026092510311297300_ehag738-B30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026092510311297300_ehag738-B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026092510311297300_ehag738-B32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2026092510311297300_ehag738-B33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026092510311297300_ehag738-B34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated Side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026092510311297300_ehag738-B35","author":"Daiichi Sankyo Europe GmbH"},{"key":"2026092510311297300_ehag738-B36","author":"Guasti L LApM, 2024"},{"key":"2026092510311297300_ehag738-B37","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026092510311297300_ehag738-B38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ahj.2022.05.021","article-title":"Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease","volume":"251","author":"Mazhar","year":"2022","journal-title":"Am Heart J"},{"key":"2026092510311297300_ehag738-B39","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1016\/j.ihj.2024.01.006","article-title":"Non adherence to lipid-lowering therapy and strategies to improve adherence","volume":"76 Suppl 1","author":"Mehta","year":"2024","journal-title":"Indian Heart J"},{"key":"2026092510311297300_ehag738-B40","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag738\/70852669\/ehag738.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag738\/70852669\/ehag738.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag738\/70852669\/ehag738.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:19Z","timestamp":1790346679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag738\/8774609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag738","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"ehag738"}}